An Integrated Approach to De-Risking Bispecific Antibody Development, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how an integrated development approach can help identify and address risks earlier in bispecific antibody programs. The featured speaker will discuss cell line development, upstream and downstream processing, analytical characterization and formulation, with case studies showing how findings in one area can inform decisions elsewhere. Attendees will also explore how preserving process knowledge through scale-up and technology transfer can reduce rework, support comparability and strengthen CMC development.

TORONTO, Oct. 20, 2026 /PRNewswire/ -- Bispecific antibodies are among the most promising and most demanding modalities in biologics today. Their dual-targeting architecture introduces molecular complexity that monoclonal antibody platforms were never designed to handle: chain mispairing, homodimers, heavy-chain clipping, aggregation and the need to confirm that both arms engage their intended targets. This webinar will explore how an integrated development approach can help identify and address these risks earlier across the CMC program.

This molecular complexity translates into real development challenges, including low and inconsistent titers from stable pools, difficult impurity clearance, complex multi-step purification, formulation instability at the concentrations needed for patient-friendly delivery and analytical methods that must resolve and characterize closely related species before batch release. Tackled in isolation, each of these problems tends to surface late, forcing rework, comparability studies and timeline delays.

Drawing on bispecific case studies, this webinar will cover how connecting cell line, upstream and downstream process development, analytical characterization and drug product development within a shared development framework can de-risk each stage by allowing findings to inform decisions across the program. Case examples will demonstrate how analytical work localized a clipping site and fed that insight back to process development to improve purity, how systematic process development roughly doubled titer to 6 to 10+ g/L while halving resin cost and how parallel formulation work delivered a stable drug product approximately 40% faster than the industry average.

The session will also examine how maintaining process knowledge from stable pool development through GMP supply and technology transfer can support comparability, reduce rework and strengthen the CMC development strategy.

Register for this webinar to learn how bispecific antibodies can be developed through an integrated approach that reduces rework, protects timelines and strengthens CMC development.

Join Amit Jogi, PhD, Global Head, Biologics Development and Manufacturing Services, Aurigene Pharmaceutical Services Ltd, for the live webinar on Wednesday, November 4, 2026, at 1:00pm EST (7:00pm CET / EU-Central).

For more information, or to register for this event, visit An Integrated Approach to De-Risking Bispecific Antibody Development.

ABOUT XTALKS

Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.

To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]

SOURCE Xtalks